BioLife Solutions, Inc. (NASDAQ:BLFS) Holdings Decreased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its position in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 2.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 62,428 shares of the medical equipment provider’s stock after selling 1,271 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in BioLife Solutions were worth $1,563,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Isthmus Partners LLC lifted its position in shares of BioLife Solutions by 34.4% in the 2nd quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 42,265 shares during the last quarter. 1620 Investment Advisors Inc. acquired a new stake in BioLife Solutions during the second quarter worth about $35,000. Quest Partners LLC bought a new position in BioLife Solutions in the third quarter worth about $57,000. GAMMA Investing LLC boosted its stake in BioLife Solutions by 29.4% in the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after acquiring an additional 748 shares during the period. Finally, Canada Pension Plan Investment Board acquired a new position in BioLife Solutions in the second quarter valued at approximately $122,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

Wall Street Analysts Forecast Growth

BLFS has been the topic of several recent research reports. Craig Hallum raised their price target on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. HC Wainwright cut their target price on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. KeyCorp upped their price target on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday. Finally, TD Cowen lifted their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $28.29.

BioLife Solutions Stock Performance

Shares of BLFS opened at $27.37 on Tuesday. The firm has a market capitalization of $1.27 billion, a PE ratio of -25.82 and a beta of 1.91. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The firm has a 50-day moving average price of $24.69 and a 200 day moving average price of $23.61. BioLife Solutions, Inc. has a 52-week low of $14.49 and a 52-week high of $28.88.

Insider Activity

In related news, EVP Aby J. Mathew sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $23.28, for a total transaction of $232,800.00. Following the completion of the transaction, the executive vice president now owns 317,716 shares of the company’s stock, valued at $7,396,428.48. This trade represents a 3.05 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders sold 66,655 shares of company stock worth $1,455,890 over the last three months. Corporate insiders own 2.20% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.